ProCE Banner Activity

IMPOWER-24: Monthly Oral Islatravir for PrEP in Cisgender Men and Transgender Women

Conference Coverage
Slideset

In a safety analysis of IMPOWER-24, once-monthly islatravir was well tolerated among people assigned male at birth who have sex with men or transgender women and who are at high risk of HIV infection. However, consistent with other islatravir studies, total lymphocyte count decreases were observed.

Released: October 14, 2024

Expiration: October 13, 2025

Share

Provided by

Provided by Clinical Care Options, LLC in partnership with the International AIDS Society  

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc. and ViiV Healthcare.

Gilead Sciences, Inc.

ViiV Healthcare

Partners

IAS

ProCE Banner